Disfunzione miocardica in corso di sepsi: Epidemiologia, significato prognostico e trattamento

Translated title of the contribution: Myocardial dysfunction during sepsis: Epidemiology, prognostic significance and treatment

Giorgia Paoli, Serafina Valente, Diego Ardissino, Gian Franco Gensini

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

About 50% of patients with sepsis show myocardial involvement characterized by biventricular enlargement, reduced contractility and diastolic dysfunction. This increases the risk of death and leads to an extremely poor prognosis in the case of severe sepsis or septic shock, with full recovery of cardiac function seen in survivors at 7-10 days. The pathogenesis of myocardial dysfunction has long been investigated and, although it is still not fully understood, seems not to be due to reduced coronary flow, but to circulating substances released by pathogens (e.g. endotoxins) and host immuno-inflammatory responses (e.g. cytokines and mechanisms related to nitric oxide). First-line therapy is causal and consists of antibiotics plus the surgical excision of the infectious focus; in the presence of severe sepsis or septic shock, it is also necessary to promptly start circulatory and multiorgan support treatment. This review describes current knowledge concerning the instrumental and clinical characteristics, pathophysiology, prognosis and therapy of myocardial dysfunction during sepsis, and briefly considers possible future therapeutic perspectives.

Original languageItalian
Pages (from-to)804-814
Number of pages11
JournalGiornale Italiano di Cardiologia
Volume12
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Sepsis
Epidemiology
Septic Shock
Recovery of Function
Therapeutics
Endotoxins
Survivors
Nitric Oxide
Cytokines
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Disfunzione miocardica in corso di sepsi : Epidemiologia, significato prognostico e trattamento. / Paoli, Giorgia; Valente, Serafina; Ardissino, Diego; Gensini, Gian Franco.

In: Giornale Italiano di Cardiologia, Vol. 12, No. 12, 12.2011, p. 804-814.

Research output: Contribution to journalArticle

Paoli, Giorgia ; Valente, Serafina ; Ardissino, Diego ; Gensini, Gian Franco. / Disfunzione miocardica in corso di sepsi : Epidemiologia, significato prognostico e trattamento. In: Giornale Italiano di Cardiologia. 2011 ; Vol. 12, No. 12. pp. 804-814.
@article{a575265e45bc42368fd3c2ed0fb1dd02,
title = "Disfunzione miocardica in corso di sepsi: Epidemiologia, significato prognostico e trattamento",
abstract = "About 50{\%} of patients with sepsis show myocardial involvement characterized by biventricular enlargement, reduced contractility and diastolic dysfunction. This increases the risk of death and leads to an extremely poor prognosis in the case of severe sepsis or septic shock, with full recovery of cardiac function seen in survivors at 7-10 days. The pathogenesis of myocardial dysfunction has long been investigated and, although it is still not fully understood, seems not to be due to reduced coronary flow, but to circulating substances released by pathogens (e.g. endotoxins) and host immuno-inflammatory responses (e.g. cytokines and mechanisms related to nitric oxide). First-line therapy is causal and consists of antibiotics plus the surgical excision of the infectious focus; in the presence of severe sepsis or septic shock, it is also necessary to promptly start circulatory and multiorgan support treatment. This review describes current knowledge concerning the instrumental and clinical characteristics, pathophysiology, prognosis and therapy of myocardial dysfunction during sepsis, and briefly considers possible future therapeutic perspectives.",
keywords = "Myocardial dysfunction, Sepsis, Septic shock",
author = "Giorgia Paoli and Serafina Valente and Diego Ardissino and Gensini, {Gian Franco}",
year = "2011",
month = "12",
doi = "10.1714/996.10825",
language = "Italian",
volume = "12",
pages = "804--814",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "12",

}

TY - JOUR

T1 - Disfunzione miocardica in corso di sepsi

T2 - Epidemiologia, significato prognostico e trattamento

AU - Paoli, Giorgia

AU - Valente, Serafina

AU - Ardissino, Diego

AU - Gensini, Gian Franco

PY - 2011/12

Y1 - 2011/12

N2 - About 50% of patients with sepsis show myocardial involvement characterized by biventricular enlargement, reduced contractility and diastolic dysfunction. This increases the risk of death and leads to an extremely poor prognosis in the case of severe sepsis or septic shock, with full recovery of cardiac function seen in survivors at 7-10 days. The pathogenesis of myocardial dysfunction has long been investigated and, although it is still not fully understood, seems not to be due to reduced coronary flow, but to circulating substances released by pathogens (e.g. endotoxins) and host immuno-inflammatory responses (e.g. cytokines and mechanisms related to nitric oxide). First-line therapy is causal and consists of antibiotics plus the surgical excision of the infectious focus; in the presence of severe sepsis or septic shock, it is also necessary to promptly start circulatory and multiorgan support treatment. This review describes current knowledge concerning the instrumental and clinical characteristics, pathophysiology, prognosis and therapy of myocardial dysfunction during sepsis, and briefly considers possible future therapeutic perspectives.

AB - About 50% of patients with sepsis show myocardial involvement characterized by biventricular enlargement, reduced contractility and diastolic dysfunction. This increases the risk of death and leads to an extremely poor prognosis in the case of severe sepsis or septic shock, with full recovery of cardiac function seen in survivors at 7-10 days. The pathogenesis of myocardial dysfunction has long been investigated and, although it is still not fully understood, seems not to be due to reduced coronary flow, but to circulating substances released by pathogens (e.g. endotoxins) and host immuno-inflammatory responses (e.g. cytokines and mechanisms related to nitric oxide). First-line therapy is causal and consists of antibiotics plus the surgical excision of the infectious focus; in the presence of severe sepsis or septic shock, it is also necessary to promptly start circulatory and multiorgan support treatment. This review describes current knowledge concerning the instrumental and clinical characteristics, pathophysiology, prognosis and therapy of myocardial dysfunction during sepsis, and briefly considers possible future therapeutic perspectives.

KW - Myocardial dysfunction

KW - Sepsis

KW - Septic shock

UR - http://www.scopus.com/inward/record.url?scp=84855840281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855840281&partnerID=8YFLogxK

U2 - 10.1714/996.10825

DO - 10.1714/996.10825

M3 - Articolo

C2 - 22158451

AN - SCOPUS:84855840281

VL - 12

SP - 804

EP - 814

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 12

ER -